Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Checkpoint Therapeutics Inc (CKPT)
NASDAQ:CKPT
RESEARCH TOOLSreports
Holding CKPT?
Track your performance easily
CKPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $4.50
Previous CloseN/A
Volume626.20K
Average Volume (3M)1.84M
Market Cap
$162.61M
Enterprise Value$91.96M
Total Cash (Recent Filing)$35.09M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 13, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding48,132,500
10 Day Avg. Volume858,661
30 Day Avg. Volume1,836,907
Standard Deviation0.21
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3252.24
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue1.28K
Enterprise Value/Gross Profit892.79
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$12.00Price Target Upside260.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Checkpoint Therapeutics News
PremiumCompany Announcements
Checkpoint Therapeutics Signs Executive Agreement with CFO
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialCheckpoint is likely to be acquired, with a projected 75% chance, as the approved drug and pipeline make it an appealing target with significant economic upside.
FDA ApprovalThe FDA approved Checkpoint's cosibelimab-ipdl ahead of the PDUFA date, making it the first and only PD-L1 blocking antibody approved for adults with certain types of cSCC.
Strategic PartnershipsCheckpoint announced a collaboration with GC Cell to explore the combination of Checkpoint's cosibelimab with GC Cell's autologous cytokine-induced killer T cell therapy, Immuncell-LC, which could enhance therapeutic options and broaden the spectrum of treatable diseases.
Bears Say
Capital RaisingThere is less than a 5% likelihood that the company will raise the capital required to commercialize UNLOXCYT itself.
Earnings PerformanceCheckpoint announced 3Q24 results, posting an EPS of ($0.23) compared to the consensus estimate of ($0.15).
Resource CommitmentIndependent commercialization of cosibelimab may provide ideal economics for Checkpoint, but manufacturing, marketing, and sales of cosibelimab would require significant commitment of resources that has yet to emerge.
---
Ownership Overview
16.23% Insiders
3.53% Mutual Funds
0.71% Other Institutional Investors
76.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CKPT FAQ
What was Checkpoint Therapeutics Inc’s price range in the past 12 months?
Checkpoint Therapeutics Inc lowest stock price was $1.38 and its highest was $4.50 in the past 12 months.
What is Checkpoint Therapeutics Inc’s market cap?
Checkpoint Therapeutics Inc’s market cap is $162.61M.
When is Checkpoint Therapeutics Inc’s upcoming earnings report date?
Checkpoint Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were Checkpoint Therapeutics Inc’s earnings last quarter?
Checkpoint Therapeutics Inc released its earnings results on Nov 12, 2024. The company reported -$0.186 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.039.
Is Checkpoint Therapeutics Inc overvalued?
According to Wall Street analysts Checkpoint Therapeutics Inc’s price is currently Undervalued.
Does Checkpoint Therapeutics Inc pay dividends?
Checkpoint Therapeutics Inc does not currently pay dividends.
What is Checkpoint Therapeutics Inc’s EPS estimate?
Checkpoint Therapeutics Inc’s EPS estimate is -0.16.
How many shares outstanding does Checkpoint Therapeutics Inc have?
Checkpoint Therapeutics Inc has 48,132,500 shares outstanding.
What happened to Checkpoint Therapeutics Inc’s price movement after its last earnings report?
Checkpoint Therapeutics Inc reported an EPS of -$0.186 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went up 4.928%.
Which hedge fund is a major shareholder of Checkpoint Therapeutics Inc?
Currently, no hedge funds are holding shares in CKPT
---
Checkpoint Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (260.36% Upside)
$12.00 (260.36% Upside)
Insider Transactions
Sold Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 14.9%
Last 30 Days ▲ 14.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.12%
12-Months-Change
Fundamentals
Return on Equity
369.09%
Trailing 12-Months
Asset Growth
133.50%
Trailing 12-Months
Company Description
Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
---
CKPT Stock 12 Month Forecast
Average Price Target
$12.00
▲(260.36% Upside)
Technical Analysis
Mustang Bio
―
Advaxis
―
Cyclacel Pharmaceuticals
―
Actinium Pharmaceuticals
―
Adaptimmune Therapeutics
―
Cidara Therapeutics
―
Best Analysts Covering CKPT
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+39.99%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +39.99% per trade.
---